Changes in demographics, clinical practices and long-term outcomes of patients with ST segment-elevation myocardial infarction who underwent coronary revascularisation in the past two decades: cohort study

Autor: Yutaka Furukawa, Kenji Nakatsuma, Takeshi Morimoto, Hiroki Shiomi, Kenji Ando, Tsukasa Inada, Moriaki Inoko, Katsuhisa Ishii, Kenji Minatoya, Takeshi Kimura, Kyohei Yamaji, Kazushige Kadota, Takashi Yamamoto, Hidenori Yaku, Erika Yamamoto, Yusuke Yoshikawa, Yoshihisa Nakagawa, Yukihito Sato, Yasuaki Takeji, Ryoji Taniguchi, Yugo Yamashita, Yukiko Mutsumura-Nakano, Ko Yamamoto, Junichi Tazaki, Satoru Suwa, Teruki Takeda, Manabu Shirotani, Natsuhiko Ehara, Tomoya Onodera, Eiji Shinoda, Hiroki Sakamoto, Yoshiharu Soga, Tatsuhiko Komiya, Eri Toda Kato, Hirotoshi Watanabe, Masayuki Fuki, Toshihiro Tamura, Hiroki Watanabe
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: BMJ Open, Vol 11, Iss 3 (2021)
Druh dokumentu: article
ISSN: 2044-6055
DOI: 10.1136/bmjopen-2020-043683
Popis: Objective To evaluate changes in demographics, clinical practices and long-term clinical outcomes of patients with ST segment-elevation myocardial infarction (STEMI) before and beyond 2010.Design Multicentre retrospective cohort study.Setting The Coronary Revascularization Demonstrating Outcome Study in Kyoto (CREDO-Kyoto) AMI Registries Wave-1 (2005–2007, 26 centres) and Wave-2 (2011–2013, 22 centres).Participants 9001 patients with STEMI who underwent coronary revascularisation (Wave-1: 4278 patients, Wave-2: 4723 patients).Primary and secondary outcome measures The primary outcome was all-cause death at 3 years. The secondary outcomes were cardiovascular death, cardiac death, sudden cardiac death, non-cardiovascular death, non-cardiac death, myocardial infarction, definite stent thrombosis, stroke, hospitalisation for heart failure, major bleeding, target vessel revascularisation, ischaemia-driven target vessel revascularisation, any coronary revascularisation and any ischaemia-driven coronary revascularisation.Results Patients in Wave-2 were older, more often had comorbidities and more often presented with cardiogenic shock than those in Wave-1. Patients in Wave-2 had shorter onset-to-balloon time and door-to-balloon time, were more frequently implanted drug-eluting stents, and received guideline-directed medication than those in Wave-1. The cumulative 3-year incidence of all-cause death was not significantly different between Wave-1 and Wave-2 (15.5% and 15.7%, p=0.77). The adjusted risk of all-cause death in Wave-2 relative to Wave-1 was not significant at 3 years (HR 0.92, 95% CI 0.83 to 1.03, p=0.14), but lower beyond 30 days (HR 0.86, 95% CI 0.75 to 0.98, p=0.03). The adjusted risks of Wave-2 relative to Wave-1 were significantly lower for definite stent thrombosis (HR 0.59, 95% CI 0.43 to 0.81, p=0.001) and for any coronary revascularisation (HR 0.75, 95% CI 0.69 to 0.81, p
Databáze: Directory of Open Access Journals